NEUROCRINE BIOSCIENCES INC
Action · US64125C1099 · NBIX · 900964 (XNAS)
125,39 USD
06.06.2025 20:00
Cours actuels de NEUROCRINE BIOSCIENCES INC
Bourse | Ticker | Devise | Dernier échange | Cours | Variation journalière |
---|---|---|---|---|---|
![]() NASDAQ |
NBIX
|
USD
|
06.06.2025 20:00
|
125,39 USD
| 124,61 USD
+0,63 %
|
![]() London |
0K6R.L
|
USD
|
06.06.2025 15:14
|
125,49 USD
| 124,61 USD
+0,71 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | 1,93 % | 5,44 % | 11,30 % | -2,26 % | -7,37 % | 8,23 % |
Profil de l'entreprise pour NEUROCRINE BIOSCIENCES INC Action
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Fonds investis
Les fonds suivants ont investi dans : NEUROCRINE BIOSCIENCES INC investi :
Fonds | Vol. en millions 301,42 | Part (%) 0,71 % |
Fonds | Vol. en millions 394,22 | Part (%) 0,11 % |
Fonds | Vol. en millions 873,57 | Part (%) 0,02 % |
Fonds | Vol. en millions 84,66 | Part (%) 0,02 % |
Fonds | Vol. en millions 112,22 | Part (%) 0,01 % |
Données de l'entreprise
Nom NEUROCRINE BIOSCIENCES INC
Société Neurocrine Biosciences, Inc.
Symbole NBIX
Site web
https://www.neurocrine.com
Marché d'origine
NASDAQ

WKN 900964
ISIN US64125C1099
Type de titre Action
Secteur Healthcare
Industrie Medical - Pharmaceuticals
PDG Mr. Kyle W. Gano Ph.D.
Capitalisation boursière 10 Mrd.
Pays États-Unis d'Amérique
Devise USD
Employés 1,8 T
Adresse 12780 El Camino Real, 92130 San Diego
Date d'introduction en bourse 2018-01-29
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | NB3.F |
London | 0K6R.L |
NASDAQ | NBIX |
Autres actions
Les investisseurs qui détiennent NEUROCRINE BIOSCIENCES INC ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.